Preseasonal prophylactic treatment with antihistamines suppresses IL-5 but not IL-33 mRNA expression in the nasal mucosa of patients with seasonal allergic rhinitis caused by Japanese cedar pollen.
CONCLUSIONS
These findings suggest that the down-regulation of interleukin (IL)-5 gene expression in collaboration with the suppression of histamine H(1) receptor (H1R) gene expression in the nasal mucosa provides the basis for better therapeutic effects of preseasonal prophylactic treatment with antihistamines in patients with seasonal allergic rhinitis caused by Japanese cedar pollen.


OBJECTIVE
The effects of prophylactic administration of antihistamines on the expression of IL-5 and IL-33 mRNA in the nasal mucosa of the patients with pollinosis were investigated.


METHODS
Eight patients had already visited the hospital before the peak pollen period and started preseasonal prophylactic treatment with antihistamines. Seventeen patients who first visited the hospital during the peak pollen period were designated as the no treatment group. After local anesthesia, nasal mucosa was obtained by scraping the inferior concha with a small spatula during the peak pollen period.


RESULTS
During the peak pollen period, the expression of IL-5 mRNA, but not that of IL-33 mRNA, in the nasal mucosa of patients receiving preseasonal prophylactic treatment with antihistamines was significantly lower in comparison with that of patients without treatment. Moreover, there was a significant correlation between the expression of IL-5 mRNA and the nasal symptoms or the expression of H1R mRNA.
Department of Otolaryngology, University of Tokushima Graduate School, Japan.
Yoshiaki
Y
Kitamura
Hiroyuki
H
Mizuguchi
Hirotaka
H
Ogishi
Wakana
W
Kuroda
Masashi
M
Hattori
Hiroyuki
H
Fukui
Noriaki
N
Takeda
D002090:Butyrophenones / Q000494:pharmacology / Q000627:therapeutic use; D032485:Cryptomeria / Q000276:immunology; D005260:Female; D006633:Histamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000067596:Interleukin-33; D015848:Interleukin-5 / Q000378:metabolism*; D007378:Interleukins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011058:Pollen / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*; D016593:Terfenadine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D002090:Butyrophenones; D006633:Histamine Antagonists; C506536:IL33 protein, human; C508599:IL5 protein, human; D000067596:Interleukin-33; D015848:Interleukin-5; D007378:Interleukins; D010880:Piperidines; D016593:Terfenadine; C093230:fexofenadine; C058249:ebastine